Novartis (NOVN: VX) added the voice of a pharmaceutical industry giant to those from retail and aerospace in warning about a no-deal Brexit on Monday.
Bosses of Airbus, Sainsbury’s and McDonald’s are among those who have warned Westminster in recent days about the implications of the UK leaving the European Union (EU) without a deal on March 29.
The risk of a no-deal scenario has been increased by Parliament’s failure to vote through a deal to date, with a Novartis statement warning: “This will be hugely impactful for patients, particularly around the supply and safety of medicines.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze